Mission Therapeutics Ltd
Interested in targeting the key pathophysiological mechanisms that underpin Cardiovascular and Metabolic diseases, to discover and develop innovative medicines for the treatment of type 2 diabetes, diabetic nephropathy, cardiovascular disease and NASH.
I am also interested in better understanding the metabolic adaptation of renal proximal tubule epithelial cells to ischemia-reperfusion injury. More specifically, how these changes in metabolism are interconnected with cellular mechanisms regulating protein homeostasis and whether this knowledge can be exploited to develop novel therapies for the treatment or prevention of acute kidney injury.
Enhanced insulin receptor, but not PI3K, signalling protects podocytes from ER stress.
Mutation of the CH1 Domain in the Histone Acetyltransferase CREBBP Results in Autism-Relevant Behaviours in Mice.
Prox1 determines hepatocyte verus cholangiocyte fate choices in hepatoblasts.
Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control.
S6K1: Reducing the RiSKs of aging.
Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases.
Liver-specific deletion of insulin receptor substrate 2 does not impair hepatic glucose and lipid metabolism in mice.
The role of insulin receptor substrate 2 in hypothalamic and beta cell function.
High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells.
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.
|Other field of expertise||